Vektor Medical

This page offers Instructions for Use (IFU) documents for Vektor Medical’s products, which are subject to national regulatory approval and may be updated.

founded by a close-knit team of engineers, scientists, doctors, and entrepreneurs

Vektor Medical develops vMap, an AI-powered, non-invasive analysis solution to help electrophysiologists locate arrhythmia sources more efficiently and accurately.

Rob previously served as President and Chief Operating Officer at Vektor Medical, overseeing clinical, regulatory, engineering, and operations. He also worked as a partner at Vorys, Sater, Seymour and Pease LLP and as Deputy Solicitor General for the State of Ohio.

request additional information about the technology

The page describes vMap, an FDA-cleared, non-invasive AI-based solution for arrhythmia analysis developed by Vektor Medical.

Vektor Medical outlines how it collects, uses, and shares user information when visiting its website.

Vektor Medical finishes enrollment for its **IMPRoVED-AF randomized clinical trial**, evaluating its cardiovascular device. The company also appoints **Brandon Allen** as **Senior Vice President of Sales**, expanding its commercial leadership ahead of potential regulatory and market milestones.

Oct 2026Business WireNews article

Vektor Medical secures a new **Category I CPT code** for its **non-invasive ventricular arrhythmia localization** technology, which analyzes **12-lead ECG data**. The approval by the AMA CPT Editorial Panel marks a key reimbursement milestone for the company’s arrhythmia-mapping solution. This development expands coverage for physicians using Vektor’s diagnostic tools in clinical settings.

Oct 2026Business WireNews article

Vektor Medical reports peer-reviewed data in *EP Europace* showing vMap-guided ablation improves one-year arrhythmia-free survival in patients with hemodynamically unstable ventricular tachycardia (VT). The study evaluates vMap’s role in mapping and ablation procedures for this high-risk patient group. Results highlight potential clinical benefits for unstable VT management.

Feb 2026Business WireNews article

Vektor Medical achieves key milestones in 2025, including expanded adoption and clinical validation for its **vMap** product. The company demonstrates growing global reach and strengthened clinical evidence, marking progress in scaling its technology. These developments highlight increased market traction and operational growth.

Jan 2026Business WireNews article